TEMOCAPRIL

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C23H28N2O5S2
Molecular Weight	476.609
Optical Activity	UNSPECIFIED
Defined Stereocenters	3 / 3
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@H]2CS[C@@H](CN(CC(O)=O)C2=O)C3=CC=CS3

InChI

InChIKey=FIQOFIRCTOWDOW-BJLQDIEVSA-N

InChI=1S/C23H28N2O5S2/c1-2-30-23(29)17(11-10-16-7-4-3-5-8-16)24-18-15-32-20(19-9-6-12-31-19)13-25(22(18)28)14-21(26)27/h3-9,12,17-18,20,24H,2,10-11,13-15H2,1H3,(H,26,27)/t17-,18-,20-/m0/s1

HIDE SMILES / InChI

Molecular Formula	C23H28N2O5S2
Molecular Weight	476.609
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	3 / 3
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/2851680
Curator's Comment: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/11686312 | https://www.ncbi.nlm.nih.gov/pubmed/19932971 | https://www.drugs.com/international/acecol.html

Temocapril is a prodrug-type angiotensin-I converting enzyme (ACE) inhibitor not approved for use in the United States but is approved in Japan and South Korea. Temocapril can also be used in hemodialysis patients without risk of serious accumulation.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Angiotensin-converting enzyme 97 Target ID: CHEMBL1808 Sources: https://www.ncbi.nlm.nih.gov/pubmed/2851680	Inhibitor 8297		3.6 nM [IC50]
Angiotensin-converting enzyme 97 Target ID: CHEMBL1808 Sources: https://www.ncbi.nlm.nih.gov/pubmed/2851680	Inhibitor 8297		3.6 nM [IC50]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Hypertension 567 Sources: https://www.pmda.go.jp/files/000153405.pdf	Primary		Approved 8429	Acecol Approved Use Unknown

PubMed

Title	Date	PubMed
Effect of temocapril hydrochloride on serum lipid levels in patients with hypertensive type 2 diabetes mellitus.	2001	11686312

Patents

Sample Use Guides

In Vivo Use Guide

A tablet containing 2 mg of temocapril hydrochloride was administered once a day in the morning, and the monitoring term was for 16 weeks.

Route of Administration: Oral

In Vitro Use Guide

A force of 1.0 g was applied, and the strips were allowed to equilibrate for 90 min. Aortic strips were exposed to 30 nM of angiotensin I (AI), which produced contractions approximately equal to 90% of the maximum response. After three successive contractions of equal size had been obtained, test drugs (CS-622 diacid) was added to the bath. Contractile responses to AI in the presence of a test drug were compared with control responses before the drug was added. The concentration of the drug was increased in a cumulative manner by a ratio of 3 at a 10 min interval to construct a concentration inhibition curve. The IC50 value was determined as the concentration inhibiting by 50% the response to AI

Substance Class	Chemical Created by `admin` on `Fri Dec 15 15:06:39 GMT 2023` Edited by `admin` on `Fri Dec 15 15:06:39 GMT 2023`
Record UNII	18IZ008EU6
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

TEMOCAPRIL

Official Name

English

TEMOCAPRIL [MI]

Common Name

English

(+)-(2S,6R)-6-(((1S)-1-CARBOXY-3-PHENYLPROPYL)AMINO)TETRAHYDRO-5-OXO-2-(2-THIENYL)-1,4-THIAZEPINE-4(5H)-ACETIC ACID, 6-ETHYL ESTER

Common Name

English

Temocapril [WHO-DD]

Common Name

English

temocapril [INN]

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C247